Traders sold shares of Relypsa Inc. (NASDAQ:RLYP) on strength during trading hours on Thursday. $116.62 million flowed into the stock on the tick-up and $162.36 million flowed out of the stock on the tick-down, for a money net flow of $45.74 million out of the stock. Of all companies tracked, Relypsa had the 0th highest net out-flow for the day. Relypsa traded up $11.85 for the day and closed at $31.95

A number of research firms have weighed in on RLYP. Brean Capital restated a “buy” rating and issued a $26.00 price target on shares of Relypsa in a research note on Sunday, April 17th. Mizuho restated a “hold” rating on shares of Relypsa in a research note on Sunday, April 17th. BTIG Research restated a “buy” rating and issued a $45.00 price target on shares of Relypsa in a research note on Sunday, April 17th. Cowen and Company restated a “buy” rating on shares of Relypsa in a research note on Sunday, May 29th. Finally, Morgan Stanley restated a “hold” rating on shares of Relypsa in a research note on Sunday, May 29th. Six research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and an average target price of $36.68.

The stock’s 50-day moving average is $19.38 and its 200 day moving average is $17.63. The company’s market cap is $1.43 billion.

Relypsa (NASDAQ:RLYP) last posted its quarterly earnings data on Wednesday, May 4th. The company reported ($1.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.46) by $0.20. During the same period in the previous year, the company earned ($0.78) earnings per share. The firm earned $12.40 million during the quarter, compared to analysts’ expectations of $6.88 million. On average, equities analysts expect that Relypsa Inc. will post ($5.95) earnings per share for the current fiscal year.

Several institutional investors recently modified their holdings of the company. Ashburton Jersey Ltd bought a new position in shares of Relypsa during the fourth quarter valued at approximately $1,725,000. Royce & Associates LLC boosted its position in shares of Relypsa by 34.6% in the fourth quarter. Royce & Associates LLC now owns 407,700 shares of the company’s stock valued at $11,554,000 after buying an additional 104,700 shares during the last quarter. GAM Holding AG boosted its position in shares of Relypsa by 91.5% in the fourth quarter. GAM Holding AG now owns 193,000 shares of the company’s stock valued at $5,470,000 after buying an additional 92,200 shares during the last quarter. ProShare Advisors LLC boosted its position in shares of Relypsa by 9.9% in the fourth quarter. ProShare Advisors LLC now owns 38,272 shares of the company’s stock valued at $1,085,000 after buying an additional 3,445 shares during the last quarter. Finally, California Public Employees Retirement System bought a new position in shares of Relypsa during the fourth quarter valued at approximately $3,826,000.

Relypsa, Inc is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of polymer-based drugs to treat conditions that are often overlooked and undertreated, but that can have a serious impact on patients’ lives and even be life-threatening. The Company’s first drug candidate is Veltassa (patiromer) for oral suspension, or Veltassa, for the treatment of hyperkalemia.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.